BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang G, Krocker JD, Kirk JL, Merwat SN, Ju H, Soloway RD, Wieck LR, Li A, Okorodudu AO, Petersen JR, Abdulla NE, Duchini A, Cicalese L, Rastellini C, Hu PC, Dong J. Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma. Clin Chem Lab Med 2014;52:899-909. [PMID: 24406287 DOI: 10.1515/cclm-2013-0885] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Tao LP, Fan XP, Fan YC, Zhao J, Gao S, Wang K. Combined detection of insulin-like growth factor-binding protein 7 promoter methylation improves the diagnostic efficacy of AFP in hepatitis B virus-associated hepatocellular carcinoma. Pathol Res Pract 2018;214:144-50. [PMID: 29108923 DOI: 10.1016/j.prp.2017.10.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Tan P, Grundy L, Makary P, Eng KH, Ramsay G, Bekheit M. The value of liquid biopsy in the diagnosis and staging of hepatocellular carcinoma: a systematic review. Transl Gastroenterol Hepatol 2021;6:54. [PMID: 34805576 DOI: 10.21037/tgh.2020.01.11] [Reference Citation Analysis]
3 Yang JC, Hu JJ, Li YX, Luo W, Liu JZ, Ye DW. Clinical Applications of Liquid Biopsy in Hepatocellular Carcinoma. Front Oncol 2022;12:781820. [PMID: 35211399 DOI: 10.3389/fonc.2022.781820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Liao W, Mao Y, Ge P, Yang H, Xu H, Lu X, Sang X, Zhong S. Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore). 2015;94:e722. [PMID: 25860220 DOI: 10.1097/md.0000000000000722] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
5 Arechederra M, Recalde M, Gárate-Rascón M, Fernández-Barrena MG, Ávila MA, Berasain C. Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease. Cancers (Basel) 2021;13:1265. [PMID: 33809263 DOI: 10.3390/cancers13061265] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Zhang J, Yuan Y, Gao S, Zhao X, Li H. Diagnostic performance of circulating cell-free DNA for hepatocellular carcinoma: a systematic review and meta-analysis. Biomark Med 2021;15:219-39. [PMID: 33470842 DOI: 10.2217/bmm-2020-0334] [Reference Citation Analysis]
7 Li X, Wang H, Li T, Wang L, Wu X, Liu J, Xu Y, Wei W. Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma. Curr Probl Cancer 2020;44:100516. [PMID: 31836136 DOI: 10.1016/j.currproblcancer.2019.100516] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
8 Cree IA, Uttley L, Buckley Woods H, Kikuchi H, Reiman A, Harnan S, Whiteman BL, Philips ST, Messenger M, Cox A, Teare D, Sheils O, Shaw J; UK Early Cancer Detection Consortium. The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review. BMC Cancer 2017;17:697. [PMID: 29061138 DOI: 10.1186/s12885-017-3693-7] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 13.0] [Reference Citation Analysis]
9 Pelizzaro F, Cardin R, Penzo B, Pinto E, Vitale A, Cillo U, Russo FP, Farinati F. Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now? Cancers (Basel) 2021;13:2274. [PMID: 34068786 DOI: 10.3390/cancers13092274] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Dhayat SA, Yang Z. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. J Cancer Res Clin Oncol 2020;146:1625-45. [PMID: 32338295 DOI: 10.1007/s00432-020-03219-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
11 Zhang Z, Chen P, Xie H, Cao P. Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta-analysis. Cancer Med 2020;9:1349-64. [PMID: 31876977 DOI: 10.1002/cam4.2799] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
12 Ammerpohl O, Scheufele S, Siebert R. Analysen epigenetischer Marker aus Liquid Biopsies: Informationen von jenseits des Genoms. Medizinische Genetik 2016;28:251-8. [DOI: 10.1007/s11825-016-0093-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Peng Y, Wei Q, He Y, Xie Q, Liang Y, Zhang L, Xia Y, Li Y, Chen W, Zhao J, Chai J. ALBI versus child-pugh in predicting outcome of patients with HCC: A systematic review. Expert Rev Gastroenterol Hepatol 2020;14:383-400. [PMID: 32240595 DOI: 10.1080/17474124.2020.1748010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zhou J, Huang A, Yang XR. Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma. J Gastrointest Cancer. 2016;47:157-167. [PMID: 26969471 DOI: 10.1007/s12029-016-9801-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
15 Su YH, Lin SY, Song W, Jain S. DNA markers in molecular diagnostics for hepatocellular carcinoma. Expert Rev Mol Diagn. 2014;14:803-817. [PMID: 25098554 DOI: 10.1586/14737159.2014.946908] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
16 Zhou Y, Wang XB, Qiu XP, Shuai Zhang, Wang C, Zheng F. CDKN2A promoter methylation and hepatocellular carcinoma risk: A meta-analysis. Clin Res Hepatol Gastroenterol 2018;42:529-41. [PMID: 30143452 DOI: 10.1016/j.clinre.2017.07.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
17 Wu X, Li J, Gassa A, Buchner D, Alakus H, Dong Q, Ren N, Liu M, Odenthal M, Stippel D, Bruns C, Zhao Y, Wahba R. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma. Int J Biol Sci 2020;16:1551-62. [PMID: 32226301 DOI: 10.7150/ijbs.44024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
18 Okajima W, Komatsu S, Ichikawa D, Miyamae M, Ohashi T, Imamura T, Kiuchi J, Nishibeppu K, Arita T, Konishi H, Shiozaki A, Morimura R, Ikoma H, Okamoto K, Otsuji E. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids. World J Gastroenterol 2017; 23(31): 5650-5668 [PMID: 28883691 DOI: 10.3748/wjg.v23.i31.5650] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
19 Li J, Han X, Yu X, Xu Z, Yang G, Liu B, Xiu P. Clinical applications of liquid biopsy as prognostic and predictive biomarkers in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. J Exp Clin Cancer Res. 2018;37:213. [PMID: 30176913 DOI: 10.1186/s13046-018-0893-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 10.8] [Reference Citation Analysis]
20 Chen VL, Xu D, Wicha MS, Lok AS, Parikh ND. Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review. Clin Gastroenterol Hepatol 2020; 18: 2879-2902. e9. [PMID: 32289533 DOI: 10.1016/j.cgh.2020.04.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
21 Huang Y, Mu J, Qi L, Ge W, Fang X, Song Y, Yuan Y, Zheng S. Diverse fragment lengths dismiss size selection for serum cell-free DNA: a comparative study of serum and plasma samples. Clin Chem Lab Med 2020;58:1451-9. [PMID: 32229658 DOI: 10.1515/cclm-2020-0078] [Reference Citation Analysis]
22 Barrera-Saldaña HA, Fernández-Garza LE, Barrera-Barrera SA. Liquid biopsy in chronic liver disease. Ann Hepatol 2021;20:100197. [PMID: 32444248 DOI: 10.1016/j.aohep.2020.03.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Zandvakili I, Lazaridis KN. Cell-free DNA testing: future applications in gastroenterology and hepatology. Therap Adv Gastroenterol 2019;12:1756284819841896. [PMID: 31019553 DOI: 10.1177/1756284819841896] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Howell JA, Sharma R. The clinical role of 'liquid biopsy' in hepatocellular carcinoma. Hepat Oncol 2016;3:45-55. [PMID: 30191026 DOI: 10.2217/hep.15.38] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
25 Luo H, Wei W, Ye Z, Zheng J, Xu RH. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends Mol Med 2021;27:482-500. [PMID: 33500194 DOI: 10.1016/j.molmed.2020.12.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
26 Trevisan França de Lima L, Broszczak D, Zhang X, Bridle K, Crawford D, Punyadeera C. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer 2020;1874:188451. [PMID: 33065194 DOI: 10.1016/j.bbcan.2020.188451] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
27 Rahat B, Ali T, Sapehia D, Mahajan A, Kaur J. Circulating Cell-Free Nucleic Acids as Epigenetic Biomarkers in Precision Medicine. Front Genet 2020;11:844. [PMID: 32849827 DOI: 10.3389/fgene.2020.00844] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
28 Reichl P, Mikulits W. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review). Oncol Rep. 2016;36:613-625. [PMID: 27278244 DOI: 10.3892/or.2016.4842] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
29 Cervena K, Vodicka P, Vymetalkova V. Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review. Mutation Research/Reviews in Mutation Research 2019;781:100-29. [DOI: 10.1016/j.mrrev.2019.05.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
30 Liu HH, Fang Y, Wang JW, Yuan XD, Fan YC, Gao S, Han LY, Wang K. Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma. Medicine (Baltimore) 2020;99:e20326. [PMID: 32443384 DOI: 10.1097/MD.0000000000020326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019;18:114. [PMID: 31269959 DOI: 10.1186/s12943-019-1043-x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 22.0] [Reference Citation Analysis]